NO20051463L - Inhaleringssammensetninger med hoy legemiddelandel - Google Patents

Inhaleringssammensetninger med hoy legemiddelandel

Info

Publication number
NO20051463L
NO20051463L NO20051463A NO20051463A NO20051463L NO 20051463 L NO20051463 L NO 20051463L NO 20051463 A NO20051463 A NO 20051463A NO 20051463 A NO20051463 A NO 20051463A NO 20051463 L NO20051463 L NO 20051463L
Authority
NO
Norway
Prior art keywords
drug content
high drug
composition
inhalation compositions
microns
Prior art date
Application number
NO20051463A
Other languages
English (en)
Inventor
Xian-Ming Zeng
Original Assignee
Norton Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd
Publication of NO20051463L publication Critical patent/NO20051463L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en tørrpulverinhalereringssammensetning som innbefatter minst 0,25 vekt-% av sammensetningen av en aktiv ingrediens med en partikkelstørrelse på mindre enn 10 mikron i diameter, og en farmasøytisk akseptabel partikulær bærer med en partikkelstørrelse på mindre enn 250 mikron i diameter. Også beskrevet er fremgangsmåter for anvendelse av sammensetningen ifølge oppfinnelsen med tørrpulverinhalerere for terapeutiske behandlinger.
NO20051463A 2002-08-21 2005-03-18 Inhaleringssammensetninger med hoy legemiddelandel NO20051463L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219511.3A GB0219511D0 (en) 2002-08-21 2002-08-21 Method of preparing dry powder inhalation compositions
PCT/US2003/026541 WO2004017942A1 (en) 2002-08-21 2003-08-21 Inhalation compositions with high drug ratios

Publications (1)

Publication Number Publication Date
NO20051463L true NO20051463L (no) 2005-05-20

Family

ID=9942744

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051463A NO20051463L (no) 2002-08-21 2005-03-18 Inhaleringssammensetninger med hoy legemiddelandel

Country Status (18)

Country Link
US (2) US8075873B2 (no)
EP (1) EP1560567A4 (no)
JP (1) JP2006517178A (no)
KR (1) KR20050088276A (no)
CN (1) CN101426476A (no)
AU (1) AU2003260049B2 (no)
BR (1) BRPI0313645A2 (no)
CA (1) CA2499280A1 (no)
DK (1) DK1545634T3 (no)
EA (1) EA007375B1 (no)
ES (1) ES2395261T3 (no)
GB (1) GB0219511D0 (no)
MX (1) MXPA05001901A (no)
NO (1) NO20051463L (no)
NZ (1) NZ538963A (no)
TN (1) TNSN05048A1 (no)
WO (1) WO2004017942A1 (no)
ZA (1) ZA200502172B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
AU2004249166B2 (en) 2003-06-13 2008-10-09 Alkermes, Inc. Low dose pharmaceutical powders for inhalation
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005102429A1 (en) 2004-04-21 2005-11-03 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
JP6251667B2 (ja) 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
IN166447B (no) * 1985-11-27 1990-05-12 Ethicon Inc
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
CA2123909C (en) * 1991-12-18 2002-10-01 Christer Carl Gustav Carling New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9700136D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6103270A (en) * 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6001336A (en) * 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP0876814A1 (en) * 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
US20030118514A1 (en) * 1998-03-26 2003-06-26 Glaxo Wellcome Inc. Compositions for inhalation
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US5965622A (en) * 1998-06-23 1999-10-12 Sepracor Inc. Desformoterol and process for its preparation
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PT1158958E (pt) * 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
US20020081266A1 (en) * 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
WO2001051030A1 (en) * 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
AP1712A (en) * 2000-10-12 2007-01-24 Boehringer Ingelheim Pharma Novel tiotropium-containing inhalation powder
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
US8273331B2 (en) * 2002-08-21 2012-09-25 Norton Healthcare Ltd. Inhalation compositions
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
PL1699434T3 (pl) * 2003-09-02 2011-09-30 Norton Healthcare Ltd Sposób wytwarzania leku
EP1699435A4 (en) * 2003-09-18 2009-05-20 Norton Healthcare Ltd PARTICLE

Also Published As

Publication number Publication date
NZ538963A (en) 2008-03-28
BRPI0313645A2 (pt) 2017-12-12
WO2004017942A1 (en) 2004-03-04
EA007375B1 (ru) 2006-10-27
ZA200502172B (en) 2006-05-31
KR20050088276A (ko) 2005-09-05
US20120065175A1 (en) 2012-03-15
AU2003260049B2 (en) 2009-09-10
AU2003260049A1 (en) 2004-03-11
DK1545634T3 (da) 2012-11-19
EP1560567A4 (en) 2007-08-22
JP2006517178A (ja) 2006-07-20
CA2499280A1 (en) 2004-03-04
TNSN05048A1 (en) 2007-05-14
WO2004017942A8 (en) 2005-06-30
MXPA05001901A (es) 2005-04-28
EA200500387A1 (ru) 2005-12-29
US20090264389A1 (en) 2009-10-22
EP1560567A1 (en) 2005-08-10
CN101426476A (zh) 2009-05-06
GB0219511D0 (en) 2002-10-02
ES2395261T3 (es) 2013-02-11
US8075873B2 (en) 2011-12-13

Similar Documents

Publication Publication Date Title
SE0102276D0 (sv) Device and method for the administration of a medicament
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
TR200101033T2 (tr) Akış direnci hafifletilmiş, aerosol halindeki aktif maddenin verilmesi
CA2477260A1 (en) Site specific delivery of co-administered drugs via inhalation
MX2010003923A (es) Formulacion farmaceutica de valsartan.
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2006002365A3 (en) Microparticles with high loadings of a bioactive agent
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
TNSN05046A1 (en) Method of preparing dry powder inhalation compositions
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
EA200301275A1 (ru) Капсулы для ингаляции
AU2002314102A1 (en) Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
TNSN06277A1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MXPA05009629A (es) Composiciones que contienen trospio.
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
BR0309115A (pt) Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco
TNSN05048A1 (en) Inhalation compositions with high drug ratios
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
BR0309114A (pt) Uso de carboidratos derivados particulados em composições farmacêuticas em pó seco, composição farmacêutica em pó seco para terapia de inalação, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, e, embalagem de medicamento
CA2499273A1 (en) Inhalation compositions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
RE Reestablishment of rights (par. 72 patents act)
FC2A Withdrawal, rejection or dismissal of laid open patent application